Stock screenerAll disclosures →
EDGAR →
TYRA
Conviction 54HealthcareScan · Tue, Sep 8, 2026TYRA$26.72-6.74%
ResistanceSupportVol 14Vol MA14 580.21K
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Price26.72
Change-6.74%
Gap-1.76%
Rel volume3.46×
Avg volume560.91K
Avg $ vol14.73M
SMA 2025.87
SMA 5028.94
SMA 20030.36
Price vs 50-7.68%
Price vs 200-12.00%
MA stackbearish
50/200 cross—
Supertrendup · 22.91
RSI (14)49
MACD hist0.33
MACD crossbull · 9d
Stoch %K / %D47 / 51
ADX (14)26
+DI / −DI28 / 19
RSI divergence—
MACD divergenceBullish
ATR %+6.27%
ADR %5.07%
52w high39.61
52w low11.82
From 52w high-32.54%
Above 52w low+126.06%
New 52w highNo
SqueezeOn · 5d
Bollinger width13.74%
%B0.74
Donchian pos47.31%
Donchian high29.56
Donchian low24.17
AVWAP (52w high)31.59
vs AVWAP high-15.42%
AVWAP (52w low)30.03
vs AVWAP low-11.03%
OBV trendFlat
Chaikin MF (20)-0.14
Today vs 20d3.46×
Avg vol (14d)580.21K
Avg vol (20d)560.91K
Avg $ vol (20d)14.73M
Market cap1.59B
RS 3m (vs SPY)+3.12%
RS 6m (vs SPY)-32.78%
RS line new highNo
Trend template4/8
Technical rank29.3
1 week+6.75%
1 month+0.79%
3 months-0.11%
6 months-20.83%
1 year+111.23%
YTD-0.26%
P/E-13.29
P/B4.51
P/S—
P/FCF-16.74
EPS-2.01
Div yield—
ROE-33.92%
ROA-31.29%
Debt/Eq—
Current14.91
EV/EBITDA-11.50
Gross margin—
Net margin—
Rev growth—
EPS growth-38.70%
Price target48.88
Target upside82.93%
Analyst ratingBuy
Institutional125.70%
Ent. value1.52B
Revenue—
Net income-45.56M
Gross profit—
Free cash flow-95.28M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out59.47M
Employees87
ListedWed, Sep 15, 2021
Free float28.09M
Float %52.1%
Short interest9.69M
Days to cover12.7d
Short volume69.1%
Squeeze score99 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.69 vs −$0.67
Last surprise-3.0% miss
Setup gradeC
Conviction54 / 100
Pattern quality—
Tech rank29.3 / 100
Group rank96 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance33.49
Support24.39
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Tyra Biosciences to Present at the Cantor Global Healthcare ConferencePR Newswire · Tue, Sep 8, 2026
- Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026PR Newswire · Fri, Sep 4, 2026
Congress activity
Disclosed STOCK Act trades in TYRA
No recent disclosed trades by Congress in TYRA. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in TYRA · 10 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Shah Rajeev M. Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
Kolchinsky Peter Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
Simson Jake Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
MORE ROBERT J Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
RA Capital Nexus Fund, L.P. Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
RA Capital Healthcare Fund LP Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
Verjee Rehan Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
RA CAPITAL MANAGEMENT, L.P. Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
Moran Susan Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
Rothenberg Stephen Michael Director · Stock Option (Right to Buy) · 2026-05-28 | Grant | 13.16K | $0 | 2026-05-28 | 2026-06-01 |
SEC filings
EDGAR filings in TYRA · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.